Patient Journey Mapping for a Leading New Cancer Drugs Manufacturer Helps Form a Company-Wide Agreement on Key Issues and Unmet Needs
What the Client Wanted
A leading new cancer drugs manufacturer wanted to comprehend the regional unmet needs of the US and European patient population in the advanced stage of the disease and understand how they can be a respected player in the therapeutic area.
The company prioritized the list of unmet needs for the patient population and identified opportunities for promoters to share their resources with each other. This nurtured a company-wide agreement on key issues and unmet needs.
New Cancer Drugs Outlook
Today, improving cancer treatments is a priority for many new cancer drugs developers, academic researchers, and funding bodies. This has led to the prosperity of innovative therapies and increased survival rates. However, there are types of cancers with massive unmet needs. New innovations will possibly add further to the challenges and complexities within drug development to meet the increased need for precision medicine.
Improving initial detection: For most human diseases, prevention is usually preferable to finding a cure, both to improve the chances of an efficacious treatment and as the less expensive approach. In cancer, early tumor detection with non-invasive imaging such as MRI, CT, and PET scans– is proving increasingly promising for discriminating between aggressive and indolent tumors. However, these are expensive interventions that also increase an individual’s exposure to radiation and can result in a high false-positive rate.
Financial troubles: The current medical insurance systems in the US, provides no financial support for companies trying to refine prevention strategies such as cancer-preventing vaccines, a strategy that has proven fruitful for human papillomaviruses.
About the Client
The client – a leading new cancer drugs manufacturer headquartered in New York City, with their research headquarters in Connecticut. The company’s annual revenue is over US$ 70 Billion.
The new cancer drugs manufacturer wanted to understand the regional unmet needs of the US and European patient population in the advanced stage of the disease and comprehend how they can be a respected player in the therapeutic area.
Summary of our patient journey mapping engagement
To gain in-depth insights into our analytics solutions for the new cancer drugs industry
With the help of Quantzig’s patient journey mapping engagement, the new cancer drugs manufacturer was able to prioritize the list of unmet needs for the patient population and recognized opportunities for promoters to share their resources with each other. This formed a company-wide agreement on key problems and unmet needs. Additionally, the company was able to classify the priority areas to increase awareness of options, improve patient quality of life, including new treatments and clinical trials. This further empowered the patients to be active in their care plans.
Patient Journey Mapping Insights
Participation in mapping the patient journey helps companies in the new cancer drugs space to establish as a trusted leader in oncology research and reinforce their promise to improve outcomes for the challenged oncology patient population across the globe.